NSABP MEMBER: MICHIGAN STATE UNIVERSITY

密歇根州立大学癌症联盟（MSUCTC）由密歇根州立大学的社区校区以及全州的社区癌症项目组成，并在密歇根州立大学主校区进行领导和协调。MSUCTC目前正在治疗和跟踪1105例长期NSABP方案的患者。应计方案将通过以下四个机制继续增加：1)增加对目前活跃的社区肿瘤学家的科学和后勤支持；2)为MSUCTC招募更多的肿瘤学家和外科医生。我们的行政工作将集中在：1)增加NSABP主校区工作人员在我们广泛分布的社区活动中的存在（例如，肿瘤委员会，大查房，医生和护理研讨会等）；2)临床试验基础设施支持，增加当地审计，以消除违反协议和减少违法行为；3)为MSU附属机构开发特定的NSABP网站；4)参与试点研究项目；5)与以往一样，我们小组将继续广泛参与NSABP的活动（董事会PI成员、乳腺委员会、结肠委员会、方案设计小组、审核组、护理委员会）。MSUCTC一直关注生活质量问题，因此，我们的计划是设计一个辅助治疗的认知效果的试点研究，这将作为一个更大的NSABP试验的模型。此外，我们将在密歇根州的美国原住民社区进行一项接受和遵守NSABP协议的研究，这将有助于该小组设计一种策略来增加这一人口。我们的机构有一个特殊的项目来促进和监督少数民族参加由NIH补充拨款支持的NSABP试验。这一经验将传达给NSABP。拥有完善的实验室，配备高效液相色谱，GLC和质谱仪器，我们机构将为小组提供与药物和激素代谢物相关的额外研究。最近，密歇根州立大学已经组建了一个强大的团队来开发靶向治疗。我们已经检测到化疗期间map -激酶的实质性变化（包括使用替代组织），这将作为NSABP方案执行期间设计试点研究的基础。我们正在为B-30方案的患者准备一份试点方案，该方案将提交给NSABP批准。密歇根州立大学的一个跨学科小组正在研究细胞周期调节基因和基因产物的相互关系和异常，以及它们对肿瘤从非侵袭性（DCIS）发展到侵袭性和转移性疾病的影响。这可能有助于预测生物行为以及治疗反应。这两个领域的研究是相辅相成的，可以帮助团队设计药物基因组学的方案。

The Michigan State University Cancer Consortium (MSUCTC) consists of the community campuses of MSU along with community cancer programs across the state, with leadership and coordination at the main MSU campus. The MSUCTC is currently treating and following 1,105 patients on long-term NSABP protocols. Accrual to protocols will continue to increase by four mechanisms: 1) Increasing the scientific and logistic support for currently active community oncologists; and 2) Recruitment of additional oncologists and surgeons to the MSUCTC. Our administrative efforts will focus on: 1) Increasing the presence of the main campus NSABP staff in the activities of our widely dispersed communities (e.g., tumor boards, grand rounds, physicians and nursing seminars, etc.); 2) Clinical trials infrastructural support by increasing local audits in order to eliminate protocol violations and decrease delinquencies; 3) Development of a specific NSABP web site for MSU affiliates; 4) Participation in pilot research projects; 5) As in the past, our group will continue to participate extensively in the NSABP activities (PI member of the board, breast committee, colon committee, protocol design group, audit group, and nursing committee. The MSUCTC has been concerned about quality of life issues, therefore, our plans are to design a pilot study of the cognitive effects of adjuvant therapy which will serve as a model for a larger NSABP trial. In addition, we will be conducting a study of acceptance and compliance with NSABP protocols in Native American communities in Michigan which will help the group design a strategy for approach to accrual of this population. Our institution has a special program to foster and monitor accrual of ethnic minorities to NSABP trials supported by NIH supplemental grants. This experience will be conveyed to the NSABP. Having a well-developed laboratory, equipped with HPLC, GLC, and Mass Spectroscopy apparatuses, our institution will offer to the group additional studies related to drug and hormone metabolites. Recently, MSU has formed a strong group developing targeted therapy. We have detected substantial changes in MAP-kinases during chemotherapy (including use of surrogate tissues) which will serve as a basis for designing pilot studies during the execution of NSABP protocols. We are in the process of preparation of a pilot protocol with patients on protocol B-30 which will be submitted to the NSABP for approval. An interdisciplinary group at MSU is studying the interrelations and abberations of cell cycle regulatory genes and gene products and their effect on tumor progression from non-invasive (DCIS) to invasive and metastatic disease. This may help to predict biologic behavior as well as treatment response. These two areas of research complement each other and may help the group design protocols with pharmacogenomic elements.